OptiNose (NASDAQ:OPTN) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of OptiNose (NASDAQ:OPTN) in a research report released on Wednesday morning,Benzinga reports. They currently have a $5.00 price objective on the stock.

OptiNose Stock Down 15.5 %

Shares of OPTN opened at $0.51 on Wednesday. The business’s 50 day moving average price is $0.76 and its 200-day moving average price is $0.96. OptiNose has a 52 week low of $0.50 and a 52 week high of $2.10. The stock has a market cap of $76.47 million, a P/E ratio of -1.81 and a beta of -0.07.

Institutional Trading of OptiNose

A number of hedge funds have recently made changes to their positions in OPTN. GSA Capital Partners LLP bought a new stake in shares of OptiNose in the 3rd quarter worth approximately $61,000. XTX Topco Ltd purchased a new position in OptiNose in the 2nd quarter worth approximately $88,000. Squarepoint Ops LLC raised its holdings in OptiNose by 173.7% in the 2nd quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after acquiring an additional 108,903 shares during the last quarter. Oracle Investment Management Inc. purchased a new position in OptiNose in the 1st quarter worth approximately $474,000. Finally, Rice Hall James & Associates LLC raised its holdings in OptiNose by 15.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock worth $764,000 after acquiring an additional 152,435 shares during the last quarter. 85.60% of the stock is owned by institutional investors.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.